Risk assessment
Risk depends on cancer type, stage, surgery, hospitalisation, immobility, central lines and systemic therapy. In myeloma, immunomodulatory drugs require risk-based prophylaxis.
Related: Haematology → · Dr. Sachita Baniya profile → · All conditions →
Treatment
Low-molecular-weight heparin, direct oral anticoagulants and warfarin are selected according to cancer type, renal function, platelet count, drug interactions and patient preference. Duration is usually at least three to six months and longer in active cancer.
- Individualised anticoagulant selection
- Renal function and drug interaction review
- Platelet count and bleeding risk monitoring
- Duration guided by active disease
- Reassessment when cancer treatment changes
Access
Dr. Baniya consults at Kathmandu Neurology Clinic & Cognitive Center, Durbar Marg, and also practises at Kathmandu Cancer Center (KCC) Nepal, Civil Service Hospital, Kathmandu, and Advanced Care Hospital. Urgent care is needed for sudden breathlessness or chest pain.